Results for tag: "Poly ADP Ribose Polymerase"

Poly ADP Ribose Polymerase (PARP) is a family of enzymes involved in DNA repair and cell signaling. PARP inhibitors are a class of drugs used to treat cancer, and have become a major focus of biotechnology research. PARP inhibitors work by blocking the activity of PARP enzymes, which can lead to cancer cell death. PARP inhibitors have been approved for the treatment of certain types of breast, ovarian, and prostate cancers. PARP inhibitors are being studied for their potential to treat other types of cancer, as well as other diseases. Research is ongoing to explore the potential of PARP inhibitors to treat neurological diseases, autoimmune diseases, and cardiovascular diseases. PARP inhibitors are being developed by a number of biotechnology companies, including AstraZeneca, AbbVie, Merck, and Pfizer. Other companies involved in the development of PARP inhibitors include GlaxoSmithKline, Novartis, and Sanofi. Show Less Read more